Latest Leishmania Stories
AHMEDABAD, India, April 23, 2015 /PRNewswire/ -- Etna Biotech, the Vaccine R & D subsidiary of Zydus, announced a collaborative program with the National Institute
Unhealing Ulcers Afflict Millions, Including U.S.
Research involving scientists at the University of York has provided important new information about transmission of human leishmaniasis, a group of infectious diseases which kills more than 100,000 people a year.
A new way to test for the parasite which causes the fatal disease leishmaniasis could help control its spread to humans and stop dogs being needlessly killed in parts of South America.
Caught in the act!
The Amphotericin B (AmB) is the main active ingredient in the most effective drug used to treat leishmaniasis, a disease which in the Western world mainly affects dogs, but in developing countries affects over 12 million people, with more than 70,000 deaths per year.
Leishmaniasis is a vector borne disease caused by different Leishmania species with different clinical manifestations.
Relapses after treatment for Leishmania infection may be due to a greater infectivity of the parasite rather than drug resistance, as has been previously thought.
A research coordinated by the UAB has succeeded in testing a vaccine against leishmaniasis.
Belgian scientists of the Institute of Tropical Medicine (ITM) in Antwerp, Belgium made a breakthrough in bridging high tech molecular biology research on microbial pathogens and the needs of the poorest of the poor.